Cascadian Therapeutics

company

About

Cascadian Therapeutics is a bio-pharmaceutical company that researches, develops, and sells therapeutic products for treatment of cancer.

  • 51 - 100

Details

Last Funding Type
Post-IPO Equity
Last Funding Money Raised
$14.90M
Industries
Biotechnology,Health Care,Therapeutics
Founded date
Jan 1, 1985
Number Of Employee
51 - 100
Operating Status
Active

Cascadian Therapeutics, a clinical-stage biopharmaceutical company, researches and develops, and sells therapeutic products for the treatment of cancer in the United States.

The company lead clinical-stage product candidate is tucatinib, an orally active and HER2-selective small molecule tyrosine kinase inhibitor, which is in two Phase Ib trials, one in combination with Kadcyla and another in combination with Xeloda and/or Herceptin. It is also developing Checkpoint kinase 1, a protein kinase that is in pre-clinical studies to regulate the cell division cycle, as well as to DNA damage and replication stress.

In addition, the company focuses on the development of novel antibodies and T-cell immunoreceptor with Ig and ITM domains, an inhibitory receptor expressed on T-cells and NK cells that negatively regulate immune response to cancers. It has a license agreement with Array BioPharma Inc. to develop, manufacture and commercialize tucatinib; research collaboration agreement with Sentinel Oncology Ltd. for the discovery of novel Chk1 inhibitors; and collaboration agreement with Adimab LLC for the discovery of novel antibodies against d immunotherapy targets in oncology.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$14.90M
Cascadian Therapeutics has raised a total of $14.90M in funding over 2 rounds. Their latest funding was raised on Sep 24, 2010 from a Post-IPO Equity round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Sep 24, 2010 Post-IPO Equity $14.90M 2 Detail

Investors

Number of Lead Investors
Number of Investors
2
Cascadian Therapeutics is funded by 2 investors. Downsview Capital and Ayer Capital Management are the most recent investors.
Investor Name Lead Investor Funding Round
Downsview Capital Post-IPO Equity
Ayer Capital Management Post-IPO Equity